Anupam Rasayan completes 50.07% acquisition of Bliss GVS Pharma

Listed Co AcquisitionOpen Offer TriggeredStrategic Transactions View source PDF Explain this filing

ANURAS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.5%Reaction day

₹1186.50

prior close

₹1187.20

announcement price

After-mkt

timing

Nifty Smallcap 250market-0.6%+0.2% vs market

Specialty Chemicals peers, median of 99sector-1.0%+0.6% vs sector

On the reaction day the stock moved 0.2 pts more than Nifty Smallcap 250 and 0.6 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.3

15m

-0.4

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.5-0.6+0.2-1.0+0.6

Next day

-0.3-0.4+0.1-1.0+0.8

-2.6-1.5-1.0-2.2-0.4

-1.7-1.2-0.6-1.9+0.1

-1.6+0.2-1.8-0.7-0.8

-1.8+0.3-2.1-0.7-1.1

-3.7-1.6-2.1-3.2-0.5

15d

-7.2-5.6-1.6-7.3+0.1

-0.7-4.3+3.5-7.6+6.9

—————

UpDownMarket · Nifty Smallcap 250Sector · Specialty Chemicals peers, median of 99Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anupam Rasayan acquired 5.09 crore shares of Bliss GVS Pharma (47.95%) under SPA, plus 22.5 lakh more on-market at Rs 723.29/share for Rs 162.74 crores. With PAC, total holding is 50.07 percent and Anupam is now a promoter of Bliss effective 28 Sept 2026. Open offer saw only 1,669 shares tendered. Bliss makes pharma products (suppositories, tablets, capsules) across 60 plus countries with Rs 799 cr FY26 turnover. Acquisition strengthens Anupam's pharma value chain from KSMs to finished formulations.

Likely market impact

Strategic acquisition gives Anupam control of a listed global pharma firm, supporting forward integration into finished dosage forms and long-term value creation.